Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 3/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19251341 | 0.79 | AGXT (0.71) | AGXTPRMT6MAPTTSHRCACNA2D1 | |
| SCHEMBL38660066 | 0.77 | NPY1R (0.43) | MAPT | |
| SCHEMBL21256823 | 0.77 | ADRB1 (0.50) | MAPT | |
| SCHEMBL38660314 | 0.77 | ADRB1 (0.56) | MAPTTSHR | |
| SCHEMBL18920849 | 0.76 | AOC2 (0.44) | MAPT | |
| SCHEMBL13451177 | 0.75 | ADRB1 (0.62) | AGXT | |
| SCHEMBL14288609 | 0.75 | AGXT (0.73) | AGXTPRMT6 | |
| SCHEMBL31511085 | 0.74 | BPTF (0.48) | MAPT | |
| SCHEMBL28994927 | 0.72 | ALDH1A1 (0.41) | MAPTTSHR | |
| SCHEMBL30286639 | 0.72 | ALDH1A1 (0.41) | MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017093299-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |